| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Review |
Departments of 1Health Sciences,2 Medical Education, University of Leicester, Leicester;3 Department of Psychology, University of Hull, Hull;4 School of Health and Related Research, University of Sheffield, Sheffield; and5 Cancer Research United Kingdom Clinical Centre, St. James’s University Hospital, Leeds, United Kingdom
Purpose: The aim of this study was to conduct a systematic review, and where possible meta-analyses, of molecular and biological tumor markers described in neuroblastoma, and to establish an evidence-based perspective on their clinical value for the screening, diagnosis, prognosis, and monitoring of patients.
Experimental Design: A well-defined, reproducible search strategy was used to identify the relevant literature from 1966 to February 2000.
Results: A total of 428 papers studying the use of 195 different tumor markers in neuroblastoma were identified. Small sample sizes, poor statistical reporting, large heterogeneity across studies (e.g., in cutoff levels), and publication bias limited meta-analysis to the area of prognosis only; MYCN, chromosome 1p, DNA index, vanillylmandelic acid:homovanillic acid ratio, CD44, Trk-A, neuron-specific enolase, lactate dehydrogenase, ferritin, and multidrug resistance were all identified as potentially important prognostic tools.
Conclusions: This systematic review forms a knowledge base of the tumor markers studied thus far in neuroblastoma, and has identified some of the most important prognostic markers, which should be considered in future research and treatment strategies. Importantly, the review has also highlighted some general problems across primary tumor marker studies, in particular poor and heterogeneous reporting. These need to be addressed to allow better clinical interpretation and enable more appropriate evidence-based reviews in the future. In particular, collaboration of cancer research groups is needed to enable bigger sample sizes, standardize methods of analysis and reporting, and facilitate the pooling of individual patient data.
This article has been cited by other articles:
|
|
 |
|
  S. Christian, R. Winkler, I. Helfrich, A. M. Boos, E. Besemfelder, D. Schadendorf, and H. G. Augustin Endosialin (Tem1) Is a Marker of Tumor-Associated Myofibroblasts and Tumor Vessel-Associated Mural Cells Am. J. Pathol., February 1, 2008; 172(2): 486 - 494. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. D. Riley, J. R. Thompson, and K. R. Abrams An alternative model for bivariate random-effects meta-analysis when the within-study correlations are unknown Biostat., January 1, 2008; 9(1): 172 - 186. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N.J. Sebire and M. Dixon-Woods Towards a new era of tissue-based diagnosis and research Chronic Illness, December 1, 2007; 3(4): 301 - 309. [Abstract] [PDF]
|
|
|
|
 |
|
 R. Wachowiak, H. C. Fiegel, J. T. Kaifi, A. Quaas, A. Krickhahn, P. G. Schurr, R. Erttmann, M. Schachner, D. Kluth, G. Sauter, et al. L1 Is Associated With Favorable Outcome in Neuroblastomas in Contrast to Adult Tumors. Ann. Surg. Oncol., December 1, 2007; 14(12): 3575 - 3580. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. V. Corrias, R. Haupt, B. Carlini, S. Parodi, L. Rivabella, A. Garaventa, V. Pistoia, and S. Dallorso Peripheral blood stem cell tumor cell contamination and survival of neuroblastoma patients. Clin. Cancer Res., October 1, 2006; 12(19): 5680 - 5685. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-M. Hsu, Y.-M. Jen, H. Lee, M.-L. Kuo, P.-N. Tsao, C.-N. Chen, D.-M. Lai, M.-T. Lin, H.-S. Lai, W.-J. Chen, et al. The Influence of Biologic Factors on the Surgical Decision in Advanced Neuroblastoma Ann. Surg. Oncol., February 1, 2006; 13(2): 238 - 244. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. McShane, D. G. Altman, W. Sauerbrei, S. E. Taube, M. Gion, and G. M. Clark Reporting Recommendations for Tumor Marker Prognostic Studies J. Clin. Oncol., December 20, 2005; 23(36): 9067 - 9072. [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. McShane, D. G. Altman, W. Sauerbrei, S. E. Taube, M. Gion, G. M. Clark, and for the Statistics Subcommittee of the NCI-EORTC W Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK) J Natl Cancer Inst, August 17, 2005; 97(16): 1180 - 1184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Kyzas, K. T. Loizou, and J. P. A. Ioannidis Selective Reporting Biases in Cancer Prognostic Factor Studies J Natl Cancer Inst, July 20, 2005; 97(14): 1043 - 1055. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |
